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Combating viral contaminants in 
CHo cells by engineering innate 
immunity
Austin W. t. Chiang1,2, Shangzhong Li2,3, Benjamin P. Kellman  1,2,4, Gouri Chattopadhyay5, 
Yaqin Zhang5, Chih-Chung Kuo1,2,3, Jahir M. Gutierrez1,2,3, Faezeh Ghazi1, Hana schmeisser6, 
patrice Ménard7, Sara Petersen Bjørn7, Bjørn G. Voldborg7, Amy S. Rosenberg5, 
Montserrat puig  5 & Nathan e. Lewis1,2,3
Viral contamination in biopharmaceutical manufacturing can lead to shortages in the supply of critical 
therapeutics. To facilitate the protection of bioprocesses, we explored the basis for the susceptibility 
of CHO cells to RNA virus infection. Upon infection with certain ssRNA and dsRNA viruses, CHO cells 
fail to generate a significant interferon (IFN) response. Nonetheless, the downstream machinery 
for generating IFN responses and its antiviral activity is intact in these cells: treatment of cells with 
exogenously-added type I IFN or poly I:C prior to infection limited the cytopathic effect from Vesicular 
stomatitis virus (VSV), Encephalomyocarditis virus (EMCV), and Reovirus-3 virus (Reo-3) in a STAT1-
dependent manner. To harness the intrinsic antiviral mechanism, we used RNA-Seq to identify two 
upstream repressors of STAT1: Gfi1 and Trim24. By knocking out these genes, the engineered CHO 
cells exhibited activation of cellular immune responses and increased resistance to the RNA viruses 
tested. Thus, omics-guided engineering of mammalian cell culture can be deployed to increase safety in 
biotherapeutic protein production among many other biomedical applications.
Chinese hamster ovary (CHO) cells are extensively used to produce biopharmaceuticals1 for numerous reasons. 
While one advantage is their reduced susceptibility to many human virus families2,3, there have been episodes 
of animal viral contamination of biopharmaceutical production runs, mostly from trace levels of viruses in raw 
materials. These infections have led to expensive decontamination efforts and threatened the supply of criti-
cal drugs4,5. Viruses that have halted production of valuable therapeutics include RNA viruses such as Cache 
Valley virus6, Epizootic hemorrhagic disease virus7, Reovirus6 and Vesivirus 21178. Thus, there is a critical need to 
understand the mechanisms by which CHO cells are infected and how the cells can be universally engineered to 
enhance their viral resistance9. For example, a strategy was proposed to inhibit infection of CHO cells by minute 
virus of mice by engineering glycosylation10. We present an alternative strategy to prevent infections of a number 
of RNA viruses with different genomic structures and strategies to interfere with the host anti-viral defense.
Many studies have investigated the cellular response to diverse viruses in mammalian cells, and detailed the 
innate immune responses that are activated upon infection. For example, type I interferon (IFN) responses reg-
ulate the innate immune response, inhibit viral infection11,12 and can be induced by treatment of cells with poly 
I:C13,14. However, the detailed mechanisms of virus infection and the antiviral response in CHO cells remain 
largely unknown. Understanding the role of type I IFN-mediated innate immune responses in CHO cells could be 
invaluable for developing effective virus-resistant CHO bioprocesses. Fortunately, recent genome sequencing15–17 
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and RNA-Seq tools have enabled the analysis of complicated cellular processes in CHO cells18,19, such as virus 
infection.
To unravel the response of CHO cells to viral infection, we infected CHO-K1 cells with RNA viruses from 
diverse virus families. The RNA viruses are of particular interest since viral RNAs are all sensed by the RIG-I/TLR3 
receptor, so broadly active resistance strategies might be engineered upon targeting relevant downstream path-
ways. We assayed the ability of activators of type I IFN pathways to induce an antiviral response in the cells. 
Specifically, we asked the following questions: (1) Can CHO-K1 cells mount a robust type I IFN response when 
infected by RNA viruses? (2) Can innate immune modulators trigger a type I IFN response of CHO-K1 cells and, 
if so, are the type I IFN levels produced sufficient to protect CHO-K1 cells from RNA virus infections? (3) Which 
biological pathways and processes are activated during virus infection and/or treatment with innate immune 
modulators, and are there common upstream regulators that govern the antiviral response? (4) Upon the iden-
tification of common upstream regulators, how can we engineer virus resistance into CHO cells for mitigating 
risk in mammalian bioprocessing? Here we address these questions, illuminate antiviral mechanisms of CHO 
cells, and guide the development of bioprocess treatments and cell engineering efforts to make CHO cells more 
resistant to viral infection.
Materials and Methods
CHO-K1 cells and RNA virus infections. The susceptibility of CHO-K1 cells to viral infection has been 
previously reported3. Since infectivity was demonstrated for viruses of a variety of families (harboring distinct 
genomic structures), we selected the following RNA viruses from three different families to be used as prototypes: 
Vesicular stomatitis virus (VSV, ATCC® VR-1238), Encephalomyocarditis virus (EMCV, ATCC® VR-129B), and 
Reovirus-3 virus (Reo-3, ATCC® VR-824). Viral stocks were generated in susceptible Vero cells as per standard 
practices using DMEM (Dulbecco’s Modified Eagle’s medium) supplemented with 10% FBS, 2 mM L-glutamine, 
100 U/ml penicillin and 100 µg/ml streptomycin (DMEM-10). Viral stocks were titered by tissue culture infec-
tious dose 50 (TCID50) on CHO-K1 cells and used to calculate the multiplicity of infection in the experiments 
(Table 1).
Virus infection procedures. Cells were seeded in cell culture plates (3 × 105 and 1.2 × 106 cells/well in 96-well and 
6-well plates, respectively) and grown overnight in RPMI-1040 supplemented with 10% FBS, 2 mM L-glutamine, 
100 U/ml penicillin and 100 µg/ml streptomycin, 10 mM Hepes, 1x non-essential amino acids and 1 mM sodium 
pyruvate (RPMI-10). IFNα/β (human IFNα (Roferon) and IFNβ (Avonex), mouse IFNα (Bei Resources, 
Manassas, VA)) as well as innate immune modulators (LPS (TLR4) (Calbiochem), CpG-oligodeoxynucleotide 
(ODN) D-ODN, 5′-GGTGCATCGATGCAGGGGG-3′20 and ODN-1555, 5′-GCTAGACGTTAGCGT-3′ (TLR9) 
(custom-synthesized at the Center for Biologics Evaluation and Research facility, FDA), imidazoquinoline R837 
(TLR7/8) (Sigma) and poly I:C-Low molecular weight/LyoVec (poly I:C) (Invivogen) were added to the cultures 
24 h prior to testing or virus infection, at the concentrations indicated in the figures. Note that, by monitoring 
changes in the gene expression levels of IFNβ and Mx1 in the cells, we established that 16–20 h would be an ade-
quate time interval for treating cells with poly I:C prior to infection (Supplementary Fig. S1). Anti-IFNβ neutral-
izing antibody (2.5 μg/ml; Abcam, Cambridge, MA cat# 186669) was also used in certain experiments, 24 h prior 
to infection. Viral infection was performed by adding virus suspensions to the cell monolayers at the indicated 
MOI in RPMI medium without serum and incubated at 37 °C, 5% CO2 for 2 h. Cell cultures were washed twice 
with 1x PBS to discard unbound virus and further incubated at 37 °C in RPMI-10 for 30 h (VSV), 54 h (EMCV) or 
78 h (Reo-3) (unless otherwise indicated in the figures). The cell harvesting time was established based on appear-
ance of cytopathic effect in approximately 50% of the cell monolayer. Cytopathic effect was visualized by crystal 
violet staining as per standard practices. We used 50% cytopathic effect to be end point in determining CHO 
cell viral susceptibility as a way to “standardize” the effect of the three viruses over the host cell and look at tran-
scriptome changes at a time in which the culture was similarly affected. Since the quantification of the response 
would be provided by the RNA-Seq data, we adopt the qualitative approach to assess the susceptibility of the cells 
to virus infection. Infection/poly I:C experiments were repeated twice, independently. In each experiment, CHO 
cells were cultured as poly I:C untreated – uninfected (media control, m), poly I:C treated – uninfected (p), poly 
I:C untreated – virus infected (Vm) and poly I:C treated – virus infected (Vp).
Western blot procedures. Cell lysates were prepared using mammalian protein extraction reagent M-PER 
(Thermo Fisher Scientific, Waltham, MA) with Protease and Halt™ phosphatase inhibitor cocktails (Thermo 
Fisher Scientific) using an equal number of cells per sample. Samples were analyzed by SDS-PAGE using 10–20% 
Tris-Glycine gels (Thermo Fisher Scientific) under reducing conditions. As a molecular weight marker, protein lad-
der (cat# 7727S) from Cell Signaling Technology (Danvers, MA) was used. Nitrocellulose membranes and iBlot™ 
transfer system (Thermo Fisher Scientific) were used for Western Blot analysis. All other reagents for Western 
Blot analyses were purchased from Thermo Fisher Scientific. Membranes were blocked with nonfat dry milk 
Virus Virus family
Genomic nucleic 
acid nature
Referenced CHO cell 
culture infection MOI
Vesicular stomatitis virus (VSV) Rabdoviridae ss (−) RNA Potts, 2008 0.003
Encephalomyocarditis virus (EMCV) Picornaviridae ss (+) RNA Potts, 2008 0.007
Reovirus 3 (Reo-3) Reoviridae ds RNA Wisher, 2005; Rabenau 1993 0.0013
Table 1. Study prototype viruses and multiplicity of infection (MOI) on CHO-K1 cells.
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(BIO-RAD, Hercules, CA) for 1 h followed by incubation with primary antibodies against STAT1, pSTAT1 (pY701, 
BD Transduction Lab, San Jose, CA), or Mx1 (gift from O. Haller, University of Freiburg, Freiburg, Germany) O/N 
at 4 °C. Secondary goat anti-mouse and anti-rabbit antibodies were purchased from Santa Cruz Biotechnology. 
SuperSignal West Femto Maximum Sensitivity Kit (Thermo Fisher Scientific) was used to develop membranes, and 
images were taken using LAS-3000 Imaging system (GE Healthcare Bio-Sciences, Pittsburgh, PA).
RNA extraction, purification, and real-time PCR. Cell cultures were re-suspended in RLT buffer 
(Qiagen) and kept at −80 °C until RNA was extracted using the RNeasy kit (Qiagen) and on-column DNAse 
Figure 1. RNA viruses induce cytopathic effects on CHO-K1 cells. (A) Cytopathic effect of the three RNA 
viruses on CHO cells upon 30 h (VSV), 54 h (EMCV) or 78 h (Reo-3) of infection. Fold change in IFNβ (B) and 
Mx1 (C) gene expressions in CHO cells infected with the three RNA viruses compared to uninfected cells at the 
same time points. (D) Several pathways and processes were enriched for differentially expressed genes following 
viral infection (m vs. Vm). (E) Top activated (red) or repressed (blue) upstream regulators following virus 
infection.
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digestion. RNA was eluted in 25 µl of DEPC water (RNAse/DNAse free); concentration and purity were tested 
by bioanalyzer. Total RNA levels for type I IFN related genes and viral genome were also assessed by RT-PCR. 
Complementary DNA synthesis was obtained from 1 μg of RNA using the High capacity cDNA RT kit (Thermo 
Fisher scientific) as per manufacturer’s instructions. Semi-quantitative PCR reactions (25 µl) consisted in 1/20 
cDNA reaction volume, 1x Power Sybr master mix (Thermo Fisher Scientific), 0.5 µM Chinese hamster-specific 
primers for IFNβ, Mx1, IRF7 and IITMP3 sequences (SAbiosciences). Eukaryotic 18S was used as a housekeeping 
Figure 2. Innate immunity genes in CHO cells are activated by poly I:C. (A) IFN-stimulated transcription 
was increased in cells treated with poly I:C /LyoVec for 24 h, but not with other TLR ligands engaging TLR9, 
TLR4 or TLR7/8. (B) Poly I:C triggered STAT1 phosphorylation when used at 1 g/L, and (C) the levels of Mx1 
protein expression were comparable to those triggered by IFNα2c. Note that, the antibodies used here and 
the assay procedures are detailed in the Methods section. (D) Several pathways and processes were enriched 
for differentially expressed genes following poly I:C treatment (m vs. p). (E) Top upstream regulators that 
are activated (red) or repressed (blue) following poly I:C treatment. All full-length blots are presented in the 
Supplementary Fig. S12.
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gene and assessed in 1X Universal master mix, 18S expression assay (1:20) (Applied Biosystems) using a 1/50 
cDNA reaction volume. Fold changes were calculated by the 2-ΔΔCt method. Note that, to be consistent, this is 
a similar qualitative approach to assess the activation of the host cell innate immune response to the virus or poly 
I:C, in which the quantification of the response would be provided by the RNA-Seq data.
cDNA library construction and Next-generation sequencing (RNA-Seq). Library preparation was 
performed with Illumina’s TruSeq Stranded mRNA Library Prep Kit High Throughput (Catalog ID: RS-122-
2103), according to manufacturer’s protocol. Final RNA libraries were first quantified by Qubit HS and then QC 
Figure 3. Poly I:C pre-treatment prevents virus infection of VCV, EMCV, and Reo-3. (A–C) Cell morphology 
(left panels) and cytopathic effect measured by crystal violet staining (right panels) of virus-infected CHO 
cells; (D) The enriched down-stream pathways under condition of Vm vs. Vp using RNA-Seq data. (E) The top 
35 upstream regulators that are activated or repressed by poly I:C pre-treatment. A full list of the activated or 
repressed upstream regulators is shown in the Table S5.
6Scientific RepoRts |          (2019) 9:8827  | https://doi.org/10.1038/s41598-019-45126-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
on Fragment Analyzer (from Advanced Analytical). Final pool of libraries was run on the NextSeq platform with 
high output flow cell configuration (NextSeq® 500/550 High Output Kit v2 (300 cycles) FC-404-2004). Raw data 
are deposited at the Gene Expression Omnibus and Short Read Archive (accession numbers: GSE119379).
RNA-Seq quantification and differential gene expression analysis. RNA-Seq quality was assessed 
using FastQC. Adapter sequences and low-quality bases were trimmed using Trimmomatic21. Sequence align-
ment was accomplished using STAR22 against the CHO genome (GCF_000419365.1_C_griseus_v1.0) with default 
parameters. HTSeq23 was used to quantify the expression of each gene. We performed differential gene expres-
sion analysis using DESeq224. After Benjamini-Hochberg FDR correction, genes with adjusted p-values less than 
0.05 and fold change greater than 1.5 were considered as differentially expressed genes (DEGs). Supplementary 
Table S1 shows the number of identified DEGs in the three different comparisons: 1) untreated – uninfected vs. 
untreated – virus infected (m vs. Vm); 2) untreated – uninfected vs. poly I:C treated – uninfected (m vs. p); and 
3) untreated – virus infected vs. poly I:C treated – virus infected (Vm vs. Vp).
Genetic engineering (Gfi1, Trim24, Gfi1/Trim24) of CHO-S cell lines. CHO-S cells (Thermo Fisher 
Scientific Cat. # A1155701) and KO clones were cultured in CD CHO medium supplemented with 8 mM 
L-glutamine and 2 mL/L of anti-clumping agent (CHO medium) in an incubator at 37 °C, 5% CO2, 95% humidity. 
Cells were transfected using FuGENE HD reagent (Promega Cat. # E2311). The day prior to transfection, viable 
cell density was adjusted to 8 × 105 cells/mL in an MD6 plate well containing 3 mL CD CHO medium supple-
mented with 8 mM L-glutamine. For each transfection, 1500 ng Cas9-2A-GFP plasmid and 1500 ng gRNA plas-
mid (see Text S1 for details about the construction of plasmids) were diluted in 75 uL OptiPro SFM. Separately, 9 
uL FuGene HD reagent was diluted in 66 uL OptiPro SFM. The diluted plasmid was added to the diluted FuGENE 
HD and incubated at room temperature for 5 minutes and the resultant 150 µL DNA/lipid mixture was added 
dropwise to the cells. For viability experiments, CHO-S KO cell lines were seeded at 3 × 106 cells in 30 ml in CHO 
medium and incubated at 37 °C, 5% CO2, 125 rpm for up to 7 days. Infections were conducted with EMCV and 
Reo-3 at the same MOI calculated in CHO-K1 cells for 2 h prior to wash cells twice to discard unbound particles. 
Control cell lines showing susceptibility to either virus were infected in parallel to those with Gfi1 and Trim24 
gene KO.
Single cell sorting, clone genotyping and expansion. Transfected cells were single cell sorted 
48 hours post transfection, using a FACSJazz, based on green fluorescence with gating determined by comparison 
to non-transfected cells. Sorting was done into MD384 well plates (Corning Cat. # 3542) containing 30 µL CD 
CHO medium supplemented with 8 mM L-glutamine, 1% antibiotic-antimycotic agent (Thermo Fisher Scientific 
Cat. # 15240-062) and 1.5% HEPES buffer (Thermo Fisher Scientific Cat. # 15630-056). After 15 days, colonies 
were transferred to an MD96F well plate (Falcon Cat. # 351172) containing 200 µL CD CHO medium supple-
mented with 8 mM L-glutamine, and 1% antibiotic-antimycotic. After additional two days, 50 µL cell suspen-
sion from each well was transferred to a MicroAmp Fast 96 well reaction plate (Thermo Fisher Scientific Cat. # 
4346907), along with 5 × 105 wildtype control cells. The plate was centrifuged at 1000 x g for 10 minutes and then 
Virus
Consis-
tency score*a
Total nodes 
(TF, TG, BP)
Transcription 
factors (TF)*b Target gene (TG)*c Biological Process (BP)*d Relations*e
30 h 5.82 21(5, 13, 3)
STAT1, IRF3, IRF5, 
IRF7, NFATC2
CASP1, CXCL10, DDX58, EIF2AK2, 
IFIH1, IL15, ISG15, Mx1/Mx2, OASL2, 
PELI1, PML, SOCS1, TNFSF10
Inhibit
Replication of virus.
Activate
Activation of phagocytes; Apoptosis of antigen 
presenting cells.
6/15 (40%)
54 h 22.47 48(7.29.12)
STAT1, IRF3, IRF5, 
IRF7, NFATC2,
TRIM24, NCOA2
BST2, C3, CASP1, CXCL10, DDX58, 
EGR2, EIF2AK2, GBP2, IFIH1, IFIT1B, 
IFIT2, IFITM3 (IITMP3), Igtp, IL15, 
ISG15, Mx1/Mx2, MYC, OASL2, PML, 
PSMB10, PSMB8, PSME2, PTGS2, 
SPP1, STAT2, TAP1, TLR3, TNFSF10, 
TRAFD1
Inhibit
Replication of virus; Infection by RNA virus; 
Infection of central nervous system.
Activate
Antiviral response; Clearance of virus; Immune 
response of antigen presenting cells; Immune 
response of phagocytes; Cytotoxicity of 
leukocytes; Function of leukocytes; Infiltration 
by T lymphocytes; Quantity of MHC Class I of 
cell surface; Cell death of myeloid cells.
21/84 (25%)
78 h 27.80 30(8, 14, 8)
STAT1, IRF5, 
NFATC2, NR3C1, 
PPARD,
ZBTB16, CDKN2A, 
EBF1
C3, CCL2, CCL7, CD36, CXCL10, 
CXCL9, DDX58, EIF2AK2, ISG15, 
MYC, THBS1, TLR3, TNFSF10, VEGFA
Activate
Activation of macrophages;
Apoptosis of myeloid cells; Cell movement of T 
lymphocytes; Cellular infiltration by leukocytes;
Damage of lung; Recruitment of leukocytes; 
Response of myeloid cells; Response of 
phagocytes.
11/64 (17%)
78 h 7.56 12(2, 7, 3) CDKN2A, ZBTB16
C3, CCL2, CCL7, CXCL10, CXCL9, 
MYC, VEGFA
Activate
Cell movement of T lymphocytes; Recruitment 
of leukocytes; Survival of organism.
1/6 (17%)
Table 2. The downstream effects of the upstream regulators from the comparison of m vs. p. *aConsistency 
score is to measure the consistency of a predicted network by IPA with the literature evidences. *b,cThe upstream 
regulators (STAT1 is highlighted in bold face) and the antiviral relating genes. *dThe biological functions known 
to associated with the regulatory networks annotated by the IPA. *eThe number of identified relationships and 
the total relationships that represent the known regulatory relationships between regulators and functions 
supported by literatures annotated by the IPA.
7Scientific RepoRts |          (2019) 9:8827  | https://doi.org/10.1038/s41598-019-45126-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
the supernatant was removed by rapid inversion. Twenty µL of 65 °C QuickExtract DNA Extraction Solution 
(Epicentre Cat. # QE09050) was added to each well and mixed. The plate was then placed in a thermocycler at 
65 °C for 15 minutes followed by 95 °C for 5 minutes. Amplicons were generated for each gene of interest per well 
using Phusion Hot Start II DNA Polymerase and verified to be present visually on a 2% agarose gel. Amplicons 
from each well had unique barcodes, allowing them to be pooled and purified using AMPure XP beads (Beckman 
Coulter Cat. # A63881) according to manufacturer’s protocol, except using 80% ethanol for washing steps and 
40 µL beads for 50 µL sample. Samples were indexed using the Nextera XT Index kit attached using 2 x KAPA HiFi 
Hot Start Ready mix (Fisher Scientific Cat. # KK2602). AMPure XP beads were used to purify the resulting PCR 
products. DNA concentrations were determined with the Qubit 2.0 Fluorometer and used to pool all indices to 
an equimolar value and diluted to a final concentration of 10 nM using 10 mM Tris pH 8.5, 0.1% Tween 20. The 
average size of the final library was verified with a Bioanalyzer 2100. The amplicon library was then sequenced on 
an Illumina MiSeq. Insertions and deletions were identified by comparison of expected versus actual amplicon 
size. Clones with frameshift indels in all alleles were selected for expansion in shake flasks (shaking at 120 rpm, 
25 mm throw), banking and characterization.
Results and Discussion
CHO-K1 cells fail to resolve infection by RNA viruses despite possessing functional type I IFN-
inducible anti-viral mechanisms. To evaluate the response of CHO cells to three different RNA viruses 
(VSV, EMCV and Reo-3; see Table 1), cells were infected and monitored for cytopathic effects and gene expres-
sion changes related to the type I IFN response. All three viruses induced a cytopathic effect (Fig. 1A, right 
panels) and a modest increase in IFNβ transcript levels in infected CHO cell cultures was measured (Fig. 1B), 
suggesting limited production of IFN. Through its cellular receptor, IFNα/β can further activate downstream 
interferon-stimulated genes known to limit viral infection both in cell culture and in vivo25,26. We noted that CHO 
cells seem to have a functional IFNα/β receptor and its activation with exogenous IFN confers resistance of CHO 
cells to VSV infection (see Supplementary Text S2 and Fig. S2). Interestingly, CHO cells expressed high levels of 
the antiviral gene Mx1 when infected with Reo-3, but not VSV and EMCV (Fig. 1C). Nevertheless, the virus-in-
duced IFN mRNA response in the host cell was insufficient to prevent cell culture destruction. These data suggest 
a possible inhibition of the antiviral type I IFN response that varies across viruses, as previously reported27,28.
To explore why the induced type I IFN failed to mount a productive antiviral response in CHO cells, we 
conducted RNA-Seq and pathway analysis using GSEA (see details in Supplementary Text S3 and Table S1). 
GSEA analysis that compared control vs. infected CHO cells (m vs. Vm) revealed the modulation of several 
immune-related gene sets and pathways activated by the virus (Fig. 1D and Supplementary Fig. S3, Table S2, and 
Text S4). Unlike VSV and EMCV, Reo-3 induced the ‘interferon alpha response’ and ‘RIG-I and MDA5-mediated 
induction of IFNα’ pathways ((p-value, NES) = (9.05 × 10−3, 3.68) and (1.12 × 10−2, 2.74), respectively). These 
findings were consistent with observations that the reovirus genome (dsRNA) can stimulate TLR3 and RIG-I to 
induce innate immune responses in other cell types29,30, in which the observed responses diverged markedly from 
the VSV and EMCV infections.
Virus
Consis-
tency score
Total nodes 
(TF, TG, BP)*a
Transcription 
factors (TF) *b Target genes (TG)*c Biological Process (BP)*d Relations*e
VSV 8.00 22(4, 15, 3)
STAT1, IRF3, 
IRF5, IRF7
CXCL10, DDX58, EIF2AK2, IFIH1, 
IL15, ISG15, JUN, Mx1/Mx2, 
OASL2, PSMB10, PSMB8, PSMB9, 
SOCS1, TAP1, TNFSF10
Inhibit
Replication of virus; Quantity of lesion.
Activate
Quantity of CD8+ T lymphocyte.
2/12 (17%)
EMCV 12.16 29(6, 19, 4)
STAT1, IRF3, 
IRF5, IRF7, 
TRIM24, ATF4
BST2, CXCL10, DDX58, EIF2AK2, 
EIF4EBP1, IFIH1, IL15, ISG15, 
Mx1/Mx2, OASL2, PSMB10, 
PSMB8, PSMB9, SLC1A5, SLC3A2, 
SLC6A9, SLC7A5, TAP1, TNFSF10
Inhibit
Replication of virus; Transport of amino acids.
Activate
Quantity of CD8+ T lymphocyte; Quantity of 
MHC Class I on cell surface.
3/24 (13%)
EMCV 7.91 18(2, 10, 6) CCND1, SMAD4
AREG, CCND2, EREG, GJA1, 
HSPA8, ITGAV, NFKBIA, PTGS2, 
SOX4, SPP1
Inhibit
Arthritis; Cell cycle progression; Cell viability; 
Growth of ovarian follicle; Proliferation of cells.
Activate
Edema.
7/12 (58%)
EMCV 6.96 19(2, 10, 7) MKL1, VDR
CAMP, CCL2, HLA-A, ICAM1, IL6, 
MMP9, PTGS2, RELB, SPP1, TNC
Inhibit
Cancer; Quantity of interleukin; Rheumatic 
Disease; Development of body trunk.
Activate
Cell death of connective tissue cells; Nephritis; 
Organismal death.
7/14 (50%)
Reo-3 5.61 21(4, 14, 3)
GFI1, NR1H3, 
NRIP1, PPARG
ACACB, CAV1, CD36, CSF3, ETS1, 
ID2, IL6, LDLR, LPL, NFKBIA, 
PDK2, PDK4, PPARA, SLC2A1
Inhibit
Oxidation of carbohydrate; Production of 
leukocytes; Quantity of vldl triglyceride in 
blood.
1/12 (8%)
Table 3. The downstream effects of the upstream regulators from the comparison of Vm vs. Vp. *aConsistency 
score is to measure the consistency of a predicted network by IPA with the literature evidences. *b,cThe upstream 
regulators (STAT1 is highlighted in bold face) and the antiviral relating genes. *dThe biological functions known 
to associated with the regulatory networks annotated by the IPA. *eThe number of identified relationships and 
the total relationships that represent the known regulatory relationships between regulators and functions 
supported by literatures annotated by the IPA.
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As we observed for Mx1, only Reo-3-infected cells showed a significant enrichment of differentially expressed 
genes involved in the type I IFN response (FDR-adjusted p-value = 9.05 × 10−3; normalized enrichment score, 
NES = 3.68). These genes contain the consensus transcription factor binding sites in the promoters that are 
mainly regulated by the transcription factor STAT1 and the interferon regulatory factors (IRF) family, such as 
IRF1, IRF3, IRF7 and IRF8 (Fig. 1E). These results are consistent with observations that the IRF family transcrip-
tion factors activate downstream immune responses in virus-infected mammalian cells31,32. In contrast, VSV and 
EMCV failed to trigger anti-viral related mechanisms (e.g., type I IFN responses) downstream of IFNβ (Figs 1D 
and S3A). Examples of a few pathways that were stimulated included ‘immune system’ (including adaptive/innate 
immune system and cytokine signaling in immune system) in VSV (FDR-adjusted p-value = 1.49 × 10−2; nor-
malized enrichment score, NES = 1.99) and the ‘G2M checkpoint’ in EMCV (p-value = 8.95 × 10−3; NES = 2.64). 
Disruption of the cell cycle affecting the G2M DNA checkpoint network has been reported for the survival of sev-
eral viruses, including HIV (ssRNA)33, EBV (dsDNA)34, JCV (DNA)35, HSV (DNA)36. However, further studies 
will need to confirm whether VSV or EMCV use a similar strategy to escape the cell defense. Nevertheless, neither 
VSV nor EMCV infection activated known upstream activators of type I IFN pathways (Fig. 1E) when analyzed 
with Ingenuity Pathway Analysis (IPA)37.
Figure 4. A STAT1-dependent regulatory network controls viral resistance (VSV and EMCV) in CHO cells. A 
STAT1-dependent regulatory network induced by the pre-treatment of poly I:C leads to the inhibition of VSV 
(A) and EMCV (B) replication in CHO cells, based on the comparison of Vm and Vp RNA-Seq. The colors 
denote the states inferred from the RNA-Seq data. For example, the blue color of TRIM24 means that TRIM24 
activity is suppressed, based on the differential expression of genes that are regulated by TRIM24.
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Poly I:C induces a robust type I interferon response in CHO cells. Type I IFN responses limit viral 
infection11,12,38, and innate immune modulators39,40 mimic pathogenic signals and stimulate pattern recognition 
receptors (PRRs), leading to the activation of downstream immune-related pathways. Intracellular PRRs, includ-
ing toll-like receptors (TLR) 7, 8 and 9, and cytosolic receptors RIG-I or MDA5, can sense viral nucleic acids and 
trigger the production of type I IFN. Thus, we asked whether CHO cell viral resistance could be improved by 
innate immune modulators.
CHO PRRs have not been studied extensively, so we first assessed the ability of synthetic ligands to stimulate 
their cognate receptors to induce a type I IFN response. CHO cells were incubated with LPS (TLR4 ligand), 
CpG-oligodeoxynucleotide (ODN) type D (activates TLR9 on human cells), ODN-1555 (activates TLR9 on 
murine cells), imidazoquinoline R837 (TLR7/8 ligand) and poly I:C-Low molecular weight/LyoVec (poly I:C) 
(activates the RIG-I/MDA-5 pathway), and subsequently tested for changes in expression of IFN stimulated genes 
with anti-viral properties. After 24 h of culture, gene expression levels of IRF7 and Mx1 increased significantly 
in cells treated with poly I:C but not in those treated with any of the other innate immune modulators (Fig. 2A). 
Furthermore, STAT1 phosphorylation and Mx1 protein levels were elevated following treatment with poly I:C or 
exogenous interferon-alpha (IFNα), which was used as a control (Fig. 2B,C).
Next, we characterized the type I IFN response induced by poly I:C by analyzing the transcriptome of 
untreated vs. treated CHO cells. Cells were cultured with poly I:C in the media for 30, 54 and 78 h after an initial 
16 h pre-incubation period (see Methods for details). GSEA of the RNA-Seq data demonstrated that poly I:C 
induced a strong ‘innate immune response’ in comparison to untreated cultures (media) (m vs. p; (p-value, NES, 
Enrichment strength) = (8.08 × 10−3, 2.98, 73%), (1.57 × 10−2, 3.95, 70%) and (3.91 × 10−3, 3.58, 78%)) evident 
in the three independently tested time points (Fig. 2D and Supplementary Fig. S3B, Text S4 and Table S3). In 
addition, poly I:C activated several upstream regulators of the type I IFN pathways (Fig. 2E). We note that the 
GSEA strength (see Supplementary Text S3) of the innate immune response induced by poly I:C (m vs. p) was 
stronger than the innate immune response seen for Reo-3 infection alone (m vs. Vm in Supplementary Fig. S3). 
Thus, CHO cells can activate the type I IFN signaling (JAK-STAT) pathway in response to poly I:C and display an 
anti-viral gene signature, which was sustained for at least 4 days.
Poly I:C-induced type I interferon response protects CHO cells from RNA virus infections. We 
next examined if the type I IFN response, induced by poly I:C, could protect CHO cells from RNA virus infections. 
We found that poly I:C pre-treatment protected CHO cells against VSV infection through the IFNβ-mediated path-
way (Supplementary Fig. S4 and Text S5), and that poly I:C protected against all three viruses tested (Fig. 3A–C). 
Cell morphology differed notably between cultures infected with virus (Vm), control uninfected cells (m), and 
poly I:C pre-treated cultures (p and Vp) (Fig. 3A–C, left panels). These morphological changes correlated with the 
cytopathic effect observed in the cell monolayers (Fig. 3A–C, right panels). At 78 h, the extent of cell culture dam-
age by Reo-3, however, was milder than by VSV and EMCV at a shorter incubation times (30 h and 54 h, respec-
tively) (Panels Vm in Fig. 3A–C), possibly since Reo-3 induced higher levels of anti-viral related genes in the CHO 
cells but VSV and EMCV did not (Fig. 1C–E). Notably, although poly I:C pre-treatment conferred protection 
of CHO cells to all three viral infections (Panels Vp in the Fig. 3A–C), striking transcriptomic differences were 
observed (Supplementary Table S4). Poly I:C pre-treatment significantly activated immune-related pathways and 
up-regulated type I IFN-related gene expression in CHO cells infected with VSV and EMCV when compared to 
non-poly I:C pre-treated cells that were infected (Vm vs. Vp) (Fig. 3D,E, Supplementary Fig. S5A,B and Table S5). 
Poly I:C pre-treatment was sufficient to induce a protective type I IFN response to VSV and EMCV. In contrast, 
for Reo-3 infection, pre-treatment with poly I:C did not further increase the levels of expression of IFN associated 
genes already observed in no pre-treated cells. The lack of enhanced expression of antiviral genes in Reo-3 Vm vs. 
Vp observed in the GSEA was further confirmed by Taqman analysis. A similar level of expression of anti-viral 
Figure 5. Identification of regulators of STAT1 as candidates for engineering the antiviral response. Schematic 
of the regulators of STAT1, which may be candidates for engineering and improving virus resistance in CHO 
cells.
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Mx1 and IITMP3 genes41–44 was obtained for CHO cells independently infected with Reo-3 (Vm), treated with 
poly I:C (p), or pre-treated with poly I:C and infected (Vp), which resulted in no differences in transcript levels 
when we compared Vm vs. Vp (Supplementary Fig. S5C). Nevertheless, the outcome of infection was surprisingly 
different in Vm or Vp samples. To understand these differences, we searched for genes that were differently mod-
ulated by poly I:C treatment in the context of Reo-3 infection. Indeed, we identified 30 genes (Supplementary 
Fig. S6 and Table S6) that were significantly up regulated (adjusted p-value < 0.05, fold change > 1.5) in the 
comparisons of m vs. Vp and m vs. p but not in the comparison of m vs. Vm. These genes are significantly 
enriched in 11 KEGG pathways (https://www.kegg.jp/kegg/) related to host-immune response (e.g., antigen 
Figure 6. RNA-Seq results of the Gfi1 and/or Trim24 KO engineered CHO cells. Gfi1 and Trim24 were 
knocked out compared to the control (susceptible) cells. Transcriptional regulatory networks were identified 
using IPA upstream regulatory analysis (A), in which the innate immunity regulatory network (JAK-STAT 
network) is indicated by the red arrow. Transcriptional factors of the identified JAK-STAT regulatory network 
in the knocked down cells (B) and the activation of immune functions following Gfi1 and/or Trim24 genetic 
engineering were illustrated (C).
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processing and presentation, p-value = 3.4 × 10−3) and processes important to virus infection (e.g., endocytosis, 
p-value = 2.5 × 10−2). We also observed many of these genes significantly enriched molecular functions: 1) RNA 
polymerase II transcription factor activity (11 genes; GO:0000981 FDR-adjusted p-value < 1.30 × 10−15) and 2) 
nucleic acid binding transcription factor activity (12 genes GO:0001071 FDR-adjusted p-value < 3.54 × 10−15) 
by gene set enrichment analysis (see Supplementary Text S3 and Table S7). This suggests that poly I:C treatment, 
16 hours prior to virus infection, pre-disposes the cell to an antiviral state and might restore the host transcription 
machinery subverted by Reo-3 virus, resulting in the protection of the CHO cells. Further experiments would be 
interesting to investigate whether these identified molecular functions using transcriptomic data could directly 
contribute to protect CHO cells from Reo-3 virus infection.
Our results revealed other processes that are differentially activated or repressed between Vm and Vp (Fig. 3D 
and Supplementary Table S4). For example, the top down-regulated Reactome pathways in the virus-infected cells 
(Vm vs. Vp) are protein translational related processes: ‘nonsense mediated decay enhanced by the exon junction 
complex’ (p-value = 3.32 × 10−2, NES = −3.50), ‘peptide chain elongation’ (p-value = 3.32 × 10−2, NES = −3.59), 
and ‘3′-UTR mediated translational regulation’ (p-value = 3.38 × 10−2, NES = −3.61). These results agree with 
Figure 7. Viral resistance (viable cell density and viability) of the Gfi1 and/or Trim24 KO engineered CHO 
cells. Gfi1 and Trim24 were knocked out and tested for resistance to EMCV and Reo-3 virus infection compared 
to the control (susceptible) cells. Cell density and viability was followed up for one week post infection (p.i.) for 
Gfi1 single knockout cells (A), Trim24 single knockout cells (B) and Gfi1 and Trim24 double knockout cells 
(C). Data shown is from three (EMCV) and two (Reo-3) independent virus infection experiments. Susceptible 
CHO cell lines were used as positive controls for EMCV and Reo-3 virus infections during the first seven 
days (Fig. S10). In some experiments, resistant cultures were passaged and followed up for an additional week 
(Fig. S11).
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studies showing viral hijacking of the host protein translation machinery during infection45, and that the activa-
tion of interferon-stimulated genes restrain virus infections by inhibiting viral transcription and/or translation38. 
All these results suggest that poly I:C treatment provides the cell with an advantageous immune state that coun-
teracts viral escape mechanisms and results in cell survival.
A STAT1-dependent regulatory network governs viral resistance in CHO cells. GSEA revealed 
that several transcriptional regulators were activated or repressed during different viral infections and poly 
I:C-treated cells (Figs 1E, 2E and 3E). Among these, NFATC2, STAT1, IRF3, IRF5, and IRF7 were consistently 
activated by poly I:C pre-treatment of CHO cells (m vs. p and Vm vs. Vp), and TRIM24 was suppressed. These 
transcription factors are involved in TLR-signaling (IRF3, IRF5, and IRF7)31 and JAK/STAT signaling (NFATC2, 
STAT1, and TRIM24). The TLR signaling pathway is a downstream mediator in virus recognition/response and in 
activating downstream type-I interferon immune responses46,47. Meanwhile, the JAK/STAT pathway contributes 
to the antiviral responses by up-regulating interferon simulated genes to rapidly eliminate virus within infected 
cells48–50. Importantly, one mechanism by which STAT1 expression and activity may be enhanced is via the poly 
I:C-induced repression of TRIM24 (an inhibitor of STAT1). The crosstalk between TLR- and JAK/STAT-signaling 
pathways is therefore important in virus clearance of infected host cells51.
To better understand the role of upstream regulators in the CHO cell viral protection, we examined the 
expression of the affected downstream target genes. Tables 2 and 3 show the regulatory pathways modulated 
by poly I:C treatment in uninfected (m vs. p; Table 2) or infected (Vm vs. Vp; Table 3) cells, and the described 
downstream effect. In cells surviving VSV and EMCV infection (Vp), we identified regulatory networks involved 
in restricting viral replication (Table 3 and Fig. 4A,B). These networks are predominantly regulated by the 6 
transcription factors (NFATC2, STAT1, IRF3, IRF5, IRF7, and TRIM24) that were also identified as transcription 
factors induced in poly I:C treated uninfected cells (p) (Table 2). These findings suggest that the induction of the 
STAT1-dependent regulatory network by poly I:C treatment allows the cell to adopt an activated state that makes 
it refractory to virus infection. In contrast, the STAT1-dependent regulatory network was not apparent when 
comparing Reo-3 infected cells untreated and treated with poly I:C (Vm vs. Vp), because both Reo-3 and poly I:C 
induce STAT1 in CHO cells (Figs 1E and 2E). Poly I:C is a structural analog of double-stranded RNA and acti-
vates similar pathways as Reo-352, such as, the NFATC2-dependent (Supplementary Fig. S7) and IRF3-dependent 
networks (Supplementary Fig. S8).
Deletion of Trim24 and Gfi1 induced CHO cell innate immunity and viral resistance. With the 
STAT1 network potentially contributing to viral resistance, we searched for upstream regulators that could be 
modulated to maximally induce STAT1. We first used the IPA upstream regulator analysis tool to obtain all the 
predicted upstream regulators (TFs) in the RNA-Seq data (comparisons: m vs. p and Vm vs. Vp). Then, we evalu-
ated these TFs for their potential to regulate the STAT1 gene. Finally, we identified sixteen statistically significant 
(p < 0.05) upstream regulators, including 13 positive and 3 negative regulators of STAT1 using IPA (Fig. 5; see 
details in Supplementary Text S6, Fig. S9 and Table S8). We hypothesized that the deletion of the most active 
repressors of STAT1 could improve virus resistance by inducing STAT1 gene expression and the downstream 
type I IFN antiviral response in the cell (Fig. 5). We identified three STAT1 repressors (Trim24, Gfi1 and Cbl) 
with a negative regulatory score and therefore potential for inhibiting STAT1 based on the RNA-Seq differential 
expression data (see details in Supplementary Text S6 and Fig. S9). However, Cbl was not present in cells infected 
with Reo-3 (Table S8). Therefore, we selected the two negative regulators, Gfi153 and Trim2454 of STAT1 and 
knocked them out in CHO-S cells using Crispr/Cas9 (see details in the Methods section). To evaluate the impact 
of gene editing on the engineered CHO-S cells, we conducted RNA-Seq in uninfected single (Gfi1 or Trim 24) 
or double (Gfi1 + Trim 24) KO cell lines (Fig. 6). Our results revealed that these cells had increased transcript 
levels of a number of genes involved in innate immunity pathways, such as those mediated by interleukins (ILs) 
(e.g IL-33 pathway (IL-1R, IL-5, IL-13, IL-33) and IL-18) (Fig. 6A) and STAT (e.g., STAT1, 3, 5B and 6)-related 
genes (Fig. 6B), leading to the upregulation of several immune functions55,56 (Fig. 6C, green bars) that could limit 
virus infection. Subsequently and as a proof of concept, we evaluated the virus susceptibility of the cells using 
Reo-3 and EMCV. We found that the Trim24 and Gfi1 single knockout clones showed resistance to Reo-3 but 
moderate or no resistance against EMCV (Fig. 7A,B), compared to virus susceptible positive control cell lines 
(Supplementary Fig. S10). Therefore, we tested viability as a measure of cell death upon virus infection. However, 
the Gfi1 + Trim24 double knockout (Supplementary Fig. 7C) showed resistance to both viruses tested, even when 
cells were passaged and cultured for an additional week (Supplementary Fig. S11). Together these results show 
that eliminating repressors of the STAT1 regulatory network contributes to the antiviral potential of CHO cells. 
Further studies are currently being conducted to better understand the mechanisms by which the double KO cells 
are resistant to these RNA viruses, specifically focusing on the role of the identified innate immunity pathways 
in enhancing the survival of the host cells, such as (1) a potential deregulation of the type I IFN response upon 
sensing the virus (directly linked to the silencing of STAT1 transcription repressor genes), and (2) alternative 
inflammatory pathways related to the IL-1 family of cytokines (IL-33 and IL18) that may be regulated by the same 
repressor genes. This knowledge will be critical to ensure the safe use of virus-resistant engineer CHO cell lines 
in bioprocesses.
Our results suggest that the genomes of these RNA viruses are sensed by the same RIG-I/TLR3 receptors 
of the host cell, even if these RNA viruses of different families have found mechanisms to overcome the innate 
immune mechanisms of the CHO cells (Fig. 1). Activation of RIG-I/TLR3 with the ligand Poly I:C prior to virus 
infection gives an advantage to the host cell over the virus by inducing a robust type I IFN response allowing its 
survival. A similar outcome appears to be reached by deleting two of the type I IFN pathway negative regulators. 
The systems biology approach to identifying transcription factors impacting RNA virus infection could be rep-
licated in the future for other virus classes, such as DNA viruses (e.g. MVM) which use other mechanisms for 
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viral sensing such as TLR9, which is not expressed in CHO cells, therefore making CHO susceptible to MVM 
infection. Thus, using our approach, regulators of innate immunity could potentially be discovered to make DNA 
virus resistance cells by simulating TLR9 or its downstream activities in CHO cells with the use of CpG ODN to 
induce a TLR9-driven type I IFN response on the cell.
Conclusions
Here we perform a genome-wide study of viral resistance in CHO, thereby demonstrating the utility of systems 
biology approaches to not only improve host cell productivity and metabolism57–59, but also to improve product 
safety. Specifically, we demonstrated that STAT1 and other key regulators are activated upon viral infection and/
or poly I:C treatment, and that engineering the regulation of innate immunity aids in viral resistance. Studies 
have shown that modulating other genetic factors can promote viral resistance in CHO cells10,60. However, our 
findings suggest novel cell engineering targets beyond those coding for cell receptors. Thus, these insights provide 
further tools to enable the development of virus-resistant hosts to improve safety and secure the availability of 
biotherapeutic products3,61,62.
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